{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:19:53Z","timestamp":1791296393610,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2010,5,28]],"date-time":"2010-05-28T00:00:00Z","timestamp":1275004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>In this phase 2 study, the activity and tolerability of the combination of bevacizumab, an inhibitor of angiogenesis, and everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), was evaluated in the treatment of patients with metastatic melanoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients with metastatic melanoma who had received up to 2 previous systemic regimens (chemotherapy and\/or immunotherapy) were eligible. Previous treatment with angiogenesis or mTOR inhibitors was not allowed. All patients received bevacizumab at a dose of 15 mg\/kg intravenously every 21 days and everolimus at a dose of 10 mg orally daily. Patients were re\u2010evaluated every 6 weeks; those with an objective response or stable disease (according to Response Evaluation Criteria in Solid Tumors [RECIST]) continued therapy until tumor progression or unacceptable toxicity occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Fifty\u2010seven patients with metastatic melanoma received a median of 4 treatment cycles (range, 1\u201014+ cycles). Seven patients (12%) achieved major responses, whereas 33 patients (58%) were found to have stable disease at the time of first evaluation. The median progression\u2010free and overall survivals were 4 months and 8.6 months, respectively. Approximately 43% of patients were alive after 12 months of follow\u2010up. The treatment regimen was well tolerated by the majority of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The combination of bevacizumab and everolimus was found to have moderate activity and was well tolerated in the treatment of patients with metastatic melanoma. Further exploration of agents with these mechanisms of action is indicated, perhaps in combination with inhibitors of the mitogen\u2010activated protein kinase (MAPK) pathway. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25320","type":"journal-article","created":{"date-parts":[[2010,5,28]],"date-time":"2010-05-28T12:58:48Z","timestamp":1275051528000},"page":"4122-4129","source":"Crossref","is-referenced-by-count":60,"title":["Bevacizumab and everolimus in the treatment of patients with metastatic melanoma"],"prefix":"10.1002","volume":"116","author":[{"given":"John D.","family":"Hainsworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Spigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Peyton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana S.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie M.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby L.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.43"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.158"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.577"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"477s","DOI":"10.1200\/jco.2007.25.18_suppl.8520","article-title":"VEGF, VEGFR1, and VEGFR2 expression in melanoma","volume":"25","author":"Mehnert JM","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"482s","DOI":"10.1200\/jco.2007.25.18_suppl.8540","article-title":"Prognostic relevance of pretreatment soluble vascular endothelial growth factors (A, C, D) and their receptors (R1, R2, and R3) in advanced melanoma patients","volume":"25","author":"Mouawad R","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"473s","DOI":"10.1200\/jco.2009.27.15_suppl.9048","article-title":"Role of circulating angiogenin TGF\u2010b1, VEGF\u2010R1, and VEGF\u2010R2 in metastatic malignant melanoma patients","volume":"27","author":"Spano J","year":"2009","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"494s","DOI":"10.1200\/jco.2008.26.15_suppl.9048","article-title":"A phase II study of PTK787 in metastatic melanoma patients","volume":"26","author":"Corrie P","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"484s","DOI":"10.1200\/jco.2008.26.15_suppl.9006","article-title":"Axitinib (AG\u2010013736) in patients with metastatic melanoma: a phase II study","volume":"26","author":"Fruehauf JP","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_10_2","first-page":"494s","article-title":"A pilot study using sunitinib malate as therapy in patients with stage IV uveal melanoma","volume":"26","author":"Chan KR","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"476s","DOI":"10.1200\/jco.2009.27.15_suppl.9061","article-title":"Nab\u2010paclitaxel and bevacizumab as first\u2010line therapy in patients with unresectable stage III and IV melanoma","volume":"27","author":"Boasberg P","year":"2009","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"487s","DOI":"10.1200\/jco.2007.25.18_suppl.8560","article-title":"Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma","volume":"25","author":"Perez DG","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"480s","DOI":"10.1200\/jco.2007.25.18_suppl.8534","article-title":"VEGF serum levels during bevacizumab plus paclitaxel combination in metastatic melanoma","volume":"25","author":"Viteri S","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8288"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"468s","DOI":"10.1200\/jco.2009.27.15_suppl.9028","article-title":"Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin","volume":"27","author":"Tarhini AA","year":"2009","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000143964.74936.d1"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602162"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21265"},{"key":"e_1_2_6_19_2","first-page":"479s","article-title":"N0377: results of NCCTG phase II trial of the mTOR inhibitor RAD\u2010001 in metastatic melanoma","volume":"25","author":"Rao RD","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_20_2","first-page":"467s","article-title":"Phase I\/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma","volume":"27","author":"Kim KB","year":"2009","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3152"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.7636"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21611"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.061"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.5448"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(09)72058-0"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.0442"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1399"},{"key":"e_1_2_6_31_2","first-page":"2881","article-title":"Loss of PTEN promotes tumor development in malignant melanoma","volume":"63","author":"Stahl JM","year":"2003","journal-title":"Cancer Res."},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2008.06.014"},{"key":"e_1_2_6_33_2","doi-asserted-by":"crossref","first-page":"461s","DOI":"10.1200\/jco.2009.27.15_suppl.9000","article-title":"Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer","volume":"27","author":"Flaherty K","year":"2009","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.1200\/jco.2009.27.15_suppl.3513","article-title":"A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors","volume":"27","author":"Schwartz GK","year":"2009","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700026"},{"key":"e_1_2_6_36_2","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K\u2010dependent feedback loop in human cancer","volume":"118","author":"Carracedo A","year":"2008","journal-title":"J Clin Invest."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25320","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:02:20Z","timestamp":1760284940000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25320"}},"subtitle":["A phase 2 trial of the Sarah Cannon Oncology Research Consortium"],"short-title":[],"issued":{"date-parts":[[2010,8,23]]},"references-count":35,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1002\/cncr.25320"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25320","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,23]]}}}